Study identifier:D9230C00005
ClinicalTrials.gov identifier:NCT06093542
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Single-blind, Single center, Placebo-controlled, Phase I study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Subcutaneous Dose Administration in Healthy Japanese Participants.
Heathy participants
Phase 1
Yes
AZD7053, Placebo
All
12
Interventional
18 Years - 60 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Apr 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD7503 Participants will subcutaneously receive AZD7503. | Drug: AZD7053 Randomised participants will receive AZD7503 subcutaneously. |
Placebo Comparator: Placebo Participants will subcutaneously receive placebo. | Drug: Placebo Randomised participants will receive placebo subcutaneously. |